On Aug. 12, the FDA updated the Emergency Use Authorizations (EUAs) for the COVID-19 vaccines made by Pfizer (NYSE:PFE) along with its partner, BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) to include a third booster dose for immunocompromised individuals. One day later, the CDC changed its stance to recommend booster doses of the two messenger RNA (mRNA) vaccines for moderately to severely immunocompromised individuals. With EUAs in hand for third booster doses, will the top COVID-19 vaccine makers rake in a lot more revenue now? Not really. Here's why Pfizer and Moderna won't make as much extra money from U.S. booster doses as you might think.One key reason why Pfizer and Moderna won't make much more money is the limited scope of the EUA expansions. The FDA said that the broader auth

Economies go in cycles, and boom times never last forever.With inflationary pressures on the rise and the economy looking more and more stable, at some point the Fed will probably raise interest rates to keep the economy from overheating, as well as tapering its asset purchases. Both of those moves would signal headwinds for the stock market. And we're also facing a wild card with the pandemic as a resurgence of virus cases raises the specter of a new round of local restrictions.

The Fed's lending practices have supported the economy in its road to recovery, and the economy has rebounded from the early, dark days of the coronavirus pandemic. But as a result of the pandemic, American and Asia industry has faced a combination of labor shortages, supply chain constraints and higher consumer demand. These, along with stimulative federal spending packages, have led to rising inflation concerns for investors, with the added complication of potential deceleration of economic growth."A real risk investors might be missing right now is the risk of stagflation, or the persistent increase in price pressures alongside slowing economic growth.”What do you think?

Key PointsThe FDA and CDC have given a thumbs-up for third booster doses of mRNA vaccines in immunocompromised individuals, but this won't translate to a lot of extra revenue for Pfizer or Moderna.There's a relatively small market in the U.S. for booster doses under the current EUAs.The U.S. government has also already secured supply deals for more than enough doses to fully vaccinate every American and give a third booster dose.On Aug. 12, the FDA updated the Emergency Use Authorizations (EUAs) for the COVID-19 vaccines made by Pfizer (NYSE:PFE) along with its partner, BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) to include a third booster dose for immunocompromised individuals. One day later, the CDC changed its stance to recommend booster doses of the two messenger RNA (mRNA) vacci